bavituximab

Source:http://linkedlifedata.com/resource/umls/id/C1707382

PDQ: An IgG3 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Chimeric anti-phosphotidylserine monoclonal antibody binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=450954&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=450954&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49088" NCI Thesaurus),NCI: A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.

Download in:

View as